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Abstract
Background: Single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) have received considerable interest for their
association with sustained virological response (SVR) when treating patients of genotype-1 hepatitis C virus (GT1-HCV)
chronic infection with pegylated interferon and ribavirin (PegIFN/RBV). This study was to investigate the predictive power of
IL28B SNPs for on-treatment responses and SVR in treatment-naı ¨ve patients with GT1-HCV chronic infection.
Methodology/Principal Findings: We analyzed ten SNPs of IL28B in 191 treatment-naı ¨ve patients with GT1-HCV chronic
infection who received PegIFN/RBV. In these patients, rapid virological response (RVR), early virological response (EVR) and
SVR were achieved in 69.6%, 95.8% and 68.6% of the patients, respectively. Multivariate analysis (odds ratio; 95% confidence
interval; P value) indicated age (0.96; 0.93–0.99; 0.012), low baseline viral load (4.65; 2.23–9.66; ,0.001) and CC genotype of
rs12979860 (7.74; 2.55–23.53; ,0.001) but no other SNPs were independent predictors for SVR. In addition, none of the ten
SNPs examined were associated with baseline viral load and stages of liver fibrosis. Regarding RVR, low baseline viral load
(2.83; 1.40–5.73; 0.004) and CC genotype of rs12979860 (10.52; 3.45–32.04; ,0.001) were two critical predictors. As for EVR,
only CC genotype of rs12979860 (36.21; 6.68–196.38; ,0.001) was the predictor. Similarly, for end of treatment response
(ETR), CC genotype of rs12979860 (15.42; 4.62–51.18; ,0.001) was the only predictor. For patients with RVR, only low
baseline viral load (3.90; 1.57–9.68; 0.003) could predict the SVR. For patients without RVR, only rs12979860 (4.60; 1.13–
18.65; 0.033) was the predictor for SVR.
Conclusions/Significance: rs12979860 is the critical predictor for RVR, EVR, ETR and SVR in treatment-naı ¨ve patients of GT1-
HCV chronic infection. Furthermore, this SNP is the only predictor for SVR in patients without RVR. These results have
provided evidence that rs12979860 is the ideal IL28B SNP for genetic testing in treating patients of GT1-HCV chronic
infection.
Citation: Lin C-Y, Chen J-Y, Lin T-N, Jeng W-J, Huang C-H, et al. (2011) IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic
Response in Patients with Hepatitis C Virus Genotype-1 Infection. PLoS ONE 6(3): e18322. doi:10.1371/journal.pone.0018322
Editor: Jan-Hendrik Niess, Ulm University, Germany
Received November 30, 2010; Accepted February 28, 2011; Published March 30, 2011
Copyright:  2011 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Science Council, Taiwan, and CMRPG 390682, 37542, 360463 from Chang Gung Memorial Hospital. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: issheen.jks@gmail.com
Introduction
A combination therapy of pegylated interferon-alpha and
ribavirin (PegIFN/RBV) is a well-accepted standard of care for
patients with chronic hepatitis C (CHC) [1]. Current strategy for
CHC treatment is to individualize the treatment duration guided
by genotype and on-treatment viral response [1,2]. With these
recommended therapies, a sustained virological response (SVR)
rate could reach 42–79% among HCV genotype 1 and 76–95%
among HCV genotype 2/3 [2]. Interestingly, better response rates
were found in Asian patients, with SVR rates around 61–79% for
HCV genotype 1 patients [3,4,5,6] and 80–95% for HCV
genotype 2/3 patients [7,8,9]. As for the response-guided
approach, rapid virological response (RVR) is regarded as an
important predictor for SVR [5,10,11]. It is also a guide for
shortening treatment duration from 48 weeks to 24 weeks for
HCV genotype 1 with low viral load [4,5,12,13] and from 24
weeks to 12–16 weeks for genotype 2/3 chronic infection
[10,14,15]. In addition, early virological response (EVR) is an
important parameter for the decision to terminate or continue
treatment because patients without EVR could hardly achieve
SVR[16]. On the other hand, undetectable virus at the end of
treatment is coined as an end-of-treatment response (ETR).
Though an ETR does not accurately predict whether an SVR will
be achieved, it is necessary for SVR to occur[1].
Host genetic factors on the treatment efficacy for chronic
hepatitis C were proposed a long time ago due to the ethnic diffe-
rences in the treatment outcome. Recent genome-wide associated
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18322studies have explored this issue and demonstrated strong evidence
that single nucleotide polymorphisms (SNPs) of Interluekin-28B
(IL28B) were significantly correlated with SVR when patients were
treated with PegIFN/RBV [17,18,19,20,21]. Notably, the frequen-
cy of advantageous C allele of rs12979860 of IL28B was reported
highest in Asians and lowest in African-Americans. In addition, the
prevalence rates of cc genotype of rs1297860 paralleled with the
SVR in each population [17]. Furthermore, these genotypes of
IL28B also correlated with the spontaneous clearance of hepatitis C
virus [18] and with viral responses during treatment [21]. Because
of its significant impact on the treatment outcome, a genetic testing
for the genotype of SNP of IL28B before deciding on treatment
strategies has been proposed [22,23]. However, several other SNPs
of IL28B were also found to be highly associated with SVR, like
rs8099917 [20], rs12980275 [19], and others [17,18,19,20].
Nevertheless, which SNP would be the most influential on SVR
was still undetermined.
We investigated these issues and tried to increase our
understanding of the predictive ability of 10 SNPs of IL28B for
RVR, EVR and SVR in a cohort of patients with GT1-HCV
chronic infection treated with PegIFN/RBV from a large medical
center.
Materials and Methods
Patients
We analyzed a prospective cohort of 213 consecutive adult
Taiwanese treatment-naı ¨ve patients with chronic hepatitis C virus
genotype 1 who visited HCV team of Department of Gastroen-
terology and Hepatology, Linkou Medical Center, Chang Gung
Memorial Hospital, and received 24 weeks of combination therapy
with PegIFN/RBV between February 2002 and December 2008,
and who agreed to provide blood samples for the human genome
study. Patients with decompensated liver disease, hepatoma, co-
infection with hepatitis B virus or with human immunodeficiency
virus, with apparent autoimmune hepatitis and alcoholic liver
disease were excluded from this cohort. All patients included in the
study had received liver biopsies that were evaluated by one
pathologist using the Metavir scoring system. HCV genotype was
determined by a genotype specific probe based assay in the 59
untranslated region (LiPA; Innogenetics, Ghent, Belgium). In these
213 patients, we excluded 22 patients who did not fit the 80/80/
80 adherence rule (less than 80% of total PEG-IFN or total RBV
doses or less than 80% of the total duration of therapy), with a final
case number of 191 (Fig. 1).
Definitions of response to treatment were undetectable serum
HCV-RNA levels 24 weeks after cessation of treatment as SVR,
undetectable serum HCV-RNA levels at 4 week after starting
treatment as RVR, at least two-log10 reduction of viral load at
week 12 after starting treatment as EVR, and undetectable virus at
the end of treatment as ETR.
The HCV-RNA levels in this study were measured using a
commercial quantitative polymerase chain reaction (PCR) assay
VERSANT HCV RNA 3.0. Assay (HCV 3.0 bDNA assay, Bayer
Diagnostics, Berkeley, Calif., lower limit of detection: 5.2610
2IU/
ml) or COBAS TaqMan HCV Test (TaqMan HCV; Roche
Molecular Systems Inc., Branchburg, N.J., lower limit of
detection: 15 IU/ml). If non-detection of HCV-RNA by VER-
SANT HCV RNA 3.0. Assay, it would be further tested by
COBASH AMPLICOR HCV Test, v2.0 (CA V2.0, Roche
Diagnostic Systems, lower limit of detection: 50 IU/ml).
Genomic DNA extraction and IL28 B Genotyping
Anti-coagulated peripheral blood was obtained from HCV
patients. Genomic DNA was isolated from EDTA anti-
coagulated peripheral blood using the Puregene DNA isolation
kit (Gentra Systems, Minneapolis, MN) as previously de-
scribed[24]. The oligonucleotide sequences flanking ten IL28B
polymorphisms were designed as primers for Taqman allelic
discrimination. The allele specific primers were labeled with a
fluorescent dye (FAM and VIC) and used in the PCR reaction.
Aliquots of the PCR product were genotyped with allele specific
probe of SNPs using real time PCR (ABI). Ten SNPs of IL28B
including rs12979860, rs11881222, rs4803219, rs8099917,
rs12980275, rs8105790, rs7248668, rs10853728, rs8103142
and rs28416813 were chosen according to previous reports
[17,18,19,20].
Figure 1. Flow diagram illustrating the selection of subiects for analysis and their treatment outcomes.
doi:10.1371/journal.pone.0018322.g001
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All patients in this study had provided written informed consent.
This study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki and was approved by the ethical
committees of Chang Gung Memorial Hospital.
Statistical analysis
Linkage disequilibrium (LD) between marker loci was assessed
and haplotype blocks were constructed using Haploview 4.1. Chi-
square tests and Fisher’s exact probability tests were used as
appropriate to compare the categorical variables of the groups.
Continuous variables were expressed as means and standard
deviations (SDs) and compared using Mann-Whitney U test or
Student’s t-test. Univariate and multivariate logistic regression
analyses for predictors of sustained virological response were
conducted using patients’ demographic, clinical variables and
IL28B SNPs. The clinical variables included gender, age, viral load
of HCV-RNA, Metavir fibrosis stage, body mass index (BMI),
Glycohemoglobin (HbA1c), albumin, aspartate transaminase,
alanine transaminase, bilirubin, gamma-glutamyl transpeptidase
and alkaline phosphatase.
The odds ratios (OR) and 95% confidence intervals (95% CI)
were also calculated. Breslow-Day test and Cochran’s-Mantel-
Haenszel test were used to estimate the homogeneity of odds ratios
(ORs) between stratified groups. All P values less than 0.05 by the
two-tailed test were considered statistically significant. Variables
that achieved a statistical significance less than 0.10 in the
univariate analysis were entered into multivariate logistic regres-
sion analysis to identify the significant independent predictive
factors. All statistical analyses were performed with statistical
software SPSS for Windows (version 16, SPSS. Inc., Chicago, IL,
USA).
Results
rs12979860 CC genotype is the most powerful predictor
among SNPs of IL28B for RVR, EVR, ETR and SVR in
chronic GT1 HCV infected patients treated with PegIFN/
RBV
Demographic characteristics of 191 CHC genotype-1 (GT1)
patients enrolled in this prospective cohort were shown in Table 1.
Among these patients, 133 (69.63%) achieved RVR, 183 (95.81%)
achieved EVR and 131 (68.59%) achieved SVR (Figure 1). From
the result of statistic analysis, the factors favoring SVR were low
baseline viral load (HCV-RNA ,0.4610
6 IU/mL), less fibrosis
stage (Metavir fibrosis score F0–F2), low body mass index (BMI),
lower gamma-glutamyl transferase (GGT), RVR and EVR
(Table 1). Ten SNPs of IL28B genetic variations were genotyped
in each patient. Two loci, rs8103142 and rs28416813, were
excluded from this analysis due to significant deviations from
Hardy-Weinberg equilibrium in genotype and allele distributions.
In addition, one haplotype block consisting of 3 SNPs, rs
11881222, rs4803219 and rs12979860, was identified due to
strong evidence of linkage disequilibrium (Figure 2) and
rs12979860 was chosen to represent this haplotype. In all the six
SNPs under analysis, five SNPs were significantly associated with
SVR except rs10853728 (Figure 3).
We then examined the predictive ability of each SNP and other
clinical baseline parameters for SVR by logistic regression
(Table 2). Interestingly, only the rs12972860 CC genotype, but
not other SNPs, together with younger age and low baseline viral
load (,0.4610
6 IU/ml) became the significant predictors for SVR
by the multivariate analysis (Table 2). However, TT genotype of
rs8099917 was also known as another important predictor for
SVR [19,20,25,26,27,28,29]. We reasoned that the impact of
rs12979860 was too strong to mask the effect of genotype of
rs8099917 on SVR. Therefore, we omitted the data of rs12979860
and re-analyzed. As shown in Table 3, without the factor of
rs12979860, the TT genotype of rs8099917, together with
younger age and low baseline viral load emerged the significant
predictors for SVR by the multivariate analysis. As for the RVR, it
is also the same SNP, rs12972860, and baseline viral load could
predict RVR by multivariate analyses (Table 4). For the EVR and
ETR, only rs12979860 was the predictor but not the baseline viral
load (Table 5 and 6).
rs12979860 CC genotype had a significant impact on the
SVR irrespective to baseline viral load
As shown in Table 2, baseline viral load and IL28B genotypes
are the two important predictors of the SVR when treated with
PegIFN/RBV. Because IL28B is one of the cytokines that play an
important role in anti-viral immunity, we then analyzed the
relationship between these SNPs and the baseline viral load and
stages of liver fibrosis. As show in Table 7, none of these SNPs
correlated with the baseline viral load and fibrosis stage. We also
studied the influence of the IL28B genotype on the SVR in
patients with either high baseline viral load or low baseline viral
load. Because rs12979860 is the single statistically significant
Table 1. Baseline characteristics of genotype I chronic
hepatitis C patients treated with PegIFN/RBV and sustained
virological response.
Variable
Total
(N=191)
Non-SVR
(N=60)
SVR
(N=131) P value
Sex, n (%) 0.131
male 123 (64.4) 26 (43.3) 42 (32.1)
female 68 (35.6) 34 (56.7) 89 (67.9)
Baseline Viral Load
(mean 6 SD)
,0.001
,0.4610
6 IU/ml 91 (47.6) 16 (26.7) 75 (57.3)
$0.4610
6 IU/ml 100 (52.4) 44 (73.3) 56 (42.7)
Fibrosis Stage, n (%) 0.021
F0-2 103 (53.9) 25 (41.7) 78 (59.5)
F3-4 88 (46.1) 35 (58.3) 53 (40.5)
Age, y (mean 6 SD) 51.4611.1 53.6610.3 50.3611.4 0.063
BMI, Kg/m
2 (mean 6 SD) 24.563.3 25.263.1 24.263.4 0.049
HbA1c, % (mean 6 SD) 5.661.0 5.761.1 5.661.0 0.443
ALB, g/dL (mean 6 SD) 4.560.4 4.460.4 4.560.3 0.507
AST, IU/L (mean 6 SD) 92.0651.6 89.662.0 93.1651.5 0.532
ALT, IU/L (mean 6 SD) 149.16107.2 129.461.2 158.26116.3 0.068
GGT, IU/L (mean 6 SD) 42.9648.5 51.9660.0 38.8641.9 0.034
ALP, IU/L (mean 6 SD) 79.5625.2 81.9627.6 78.3624.0 0.443
Bilirubin, mg/dL
(mean 6 SD)
0.960.3 1.060.3 0.960.3 0.213
RVR, n (%) 133 (69.6) 28 (46.7) 105 (80.2) ,0.001
EVR, n (%) 183 (95.8) 54 (90.0) 129 (98.5) 0.007
BMI: body mass index. ALB: albumin; AST: aspartate transaminase; ALT: alanine
transaminase; GGT: gamma-glutamyl transpeptidase; ALP: alkaline phosphatase;
SVR: sustained viralogical response; RVR: rapid virological response; EVR: early
virological response.
doi:10.1371/journal.pone.0018322.t001
IL28B rs12979860 Predict Response in HCV Hepatitis
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18322Figure 3. IL28B genetic association with sustained virological response in patients with GT1-HCV infection treated with PegIFN/
RBV. Percentages of patients of different genotypes with SVR in eight different SNPs groups were shown. Numbers of patients were also shown
below each genotype.
doi:10.1371/journal.pone.0018322.g003
Figure 2. Pairwise linkage disequilibrium (LD) patterns for eight polymorphisms through IL28B regions (chromosome 19,
nucleotide positions 44,426,620–44,436,990).
doi:10.1371/journal.pone.0018322.g002
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locus in the groups of either high or low baseline viral load. As
shown in Table 8, the genotype of rs12979860 was significantly
associated with the SVR in both groups of high baseline viral load
or low baseline viral load. Furthermore, the odds ratios between
these two groups had no difference (Odds ratio, low viral load vs.
high viral load: 6.37 vs.5.99, p=0.956, by Cochran’s and Mantel-
Haenszel statistics). Therefore, in addition to the findings that this
SNP had no relationship with baseline viral load, the impact of the
SNP on SVR remained similar either in the group of high baseline
viral load or low baseline viral load.
rs12979860 CC genotype could not predict SVR in
patients with RVR but could in patients without RVR
RVR is an important predictor for SVR and a useful guide in
treating patients with chronic hepatitis C [1,2]. In the present
study, for patients with RVR, SVR was achieved in 79.0% of the
instances, significantly higher than patients without RVR (SVR:
44.83%, P ,0.001). We evaluated the influence of these SNPs on
the SVR in these two groups of patients. In patients with RVR,
only low baseline viral load was a significant predictor for SVR but
not any SNPs of IL28B or other clinical parameters (Table 9). On
the contrary, in patients without RVR, only CC genotype of
rs12979860 could predict the SVR but not other clinical
parameters including baseline viral load (Table 10).
Taken together, we identified rs12979860, one of the 10 SNPs
of IL28B, to be the most powerful predictor for RVR, EVR, ETR
and SVR in GT1 HCV infected patients treated with PegIFN/
RBV. In addition, rs12979860 genotype could predict the SVR in
patients without RVR but could not in patients with RVR.
Discussion
Four seminal papers had recently revealed a significant impact
of IL28B polymorphisms on the treatment outcome of patients
with chronic hepatitis C [17,18,19,20]. Subsequently, several
investigators also published similar observations in different
populations different loci of SNPs of IL28B [21,25,26,27,28,29,
30,31,32,33,34,35]. Herein, we extended these observations and
demonstrated that rs12972860 is the most powerful SNP predictor
for RVR, EVR, ETR and SVR in patients of CHC genotype 1
treated with PegIFN/RBV. Furthermore, we also demonstrated
that this SNP could only predict the SVR in patients without RVR
but could not predict the SVR in patients with RVR.
Based on previous reports on the SNPs of IL28B [17,18,19,20],
we had genotyped ten different SNPs of IL28B in our patient
cohort. These ten SNPs were most strongly associated with SVR
and were also found at the IFN-l gene cluster [17,18,19,20]. We
excluded two loci, rs8103142 and rs28416813, from analysis due
to significant deviations from Hardy-Weinberg equilibrium in
Table 2. Factors predicted SVR to Peg-IFN/RBV treatment in
genotype I chronic hepatitis C patients by univariate and
multivariate Logistic regression analysis.
Baseline Predictors Odds Ratio 95% CI p value
Univariable Age (years old) 0.97 0.95–1.00 0.064
Baseline Viral Load 3.68 1.89–7.19 ,0.001
Fibrosis stage (Metavir) 2.06 1.11–3.83 0.002
BMI (Kg/m
2) 0.92 0.83–1.00 0.060
ALT (IU/L) 1.00 0.99–1.01 0.090
GGT (IU/L) 1.00 0.99–1.00 0.109
rs12979860 4.90 1.84–13.03 0.001
rs8099917 4.25 1.66–10.92 0.003
rs12980275 3.84 1.48–9.99 0.006
rs8105790 4.25 1.66–10.92 0.003
rs7248668 3.84 1.48–9.99 0.006
rs10853728 1.41 0.75–2.66 0.285
Multivariable Age (years old) 0.96 0.93–0.99 0.012
Baseline Viral Load
$0.4610
6 IU/ml 1
,0.4610
6 IU/ml 4.65 2.23–9.66 ,0.001
rs12979860
CT/TT genotype 1
CC genotype 7.74 2.55–23.53 ,0.001
UV: univariate logistic regression analysis. MV: multivariate logistic regression
analysis.
OR: odds ratio; CI: confidence interval. Fibrosis stage: Metavir scoring system.
doi:10.1371/journal.pone.0018322.t002
Table 3. Factors predicted SVR to Peg-IFN/RBV treatment in
genotype I chronic hepatitis C patients by univariate and
multivariate Logistic regression analysis excluding
rs12979860.
Baseline Predictors Odds Ratio 95% CI p value
Multivariable Age (years old) 0.96 0.93–0.99 0.014
Baseline Viral Load
$0.4610
6 IU/ml 1
,0.4610
6 IU/ml 4.42 2.15–9.08 ,0.001
rs8099917
GG/GT genotype 1
TT genotype 6.11 2.12–17.64 0.001
doi:10.1371/journal.pone.0018322.t003
Table 4. Factors predicted RVR to Peg-IFN/RBV treatment in
genotype I chronic hepatitis C patients by univariate and
multivariate Logistic regression analysis.
Baseline Predictors Odds Ratio 95% CI p value
Univariable Baseline Viral Load 2.42 1.27–4.62 0.007
HbA1c (%) 0.74 0.55–0.99 0.046
rs12979860 8.93 3.07–26.02 ,0.001
rs8099917 4.51 1.76–11.61 0.002
rs12980275 6.74 2.44–18.60 ,0.001
rs8105790 4.51 1.76–11.61 0.002
rs7248668 6.74 2.44–18.60 ,0.001
rs10853728 1.53 0.81–2.89 0.192
Multivariable Baseline Viral Load
$0.4610
6 IU/ml 1
,0.4610
6 IU/ml 2.83 1.40–5.73 0.004
rs12979860
CT/TT genotype 1
CC genotype 10.52 3.45–32.04 ,0.001
doi:10.1371/journal.pone.0018322.t004
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rs8103142, was a nonsynonymous SNP, within the IL28B gene
that encodes a lysine to arginine substitution at position 70
(K70R). Another locus, rs28416813, was a G to C substitution at
37 base pairs upstream of the translation initiation site[23]. In
addition, we also found one haplotype block and we chose
rs12979860 to represent this haplotype because this locus was
frequently reported in previous literatures [17,18,29,30,31,
32,33,34,35]. In total, 5 SNPs were significantly correlated with
the SVR except one SNP, rs10853728, which was not. This SNP,
rs10853728, had been reported to be associated with SVR in
Japanese population with GT1 HCV infection [19] but was not
associated with RVR and SVR in Taiwanese patients with GT2/3
HCV infection [36].
However, we found the genotype of rs12979860, but not other
SNPs, together with age and viral load became the predictors of
SVR. rs12979860 is the frequently mentioned SNP of IL28B
related to SVR [17,18,29,30,31,32,33,34,35], and represents a
haplotype block. rs8099917 was another frequently reported SNP
for SVR in GT1 HCV infected patients [19,20,25,26,27,28].
rs12979860 and rs8099917 reside 3 and 8 kilobases, respectively,
upstream of the IL28B gene encoding IFN-l-3 [23]. In our
analysis, rs8099917 became the predictor for SVR only after
omitting the data of rs12979860. Therefore, though several SNPs
of IL28B had been claimed to be important for predicting SVR, it
is clear the rs12979860 is the key predictor among these SNPs for
SVR in GT1 HCV infected patients.
Concerning the relationship between baseline viral load and
SNPs of IL28B, the results from previous reports were not
consistent. Some reports claimed the baseline viral load was
correlated with the genotype of the SNP but others did not
[17,28,32,34,37]. Our data showed no relationship between
baseline viral load and the SNPs. In addition, we also
demonstrated that in both groups of high viral load and low viral
load, SNP of IL28B could predict the SVR with similar predictive
ability. Therefore, in our cohort, SNP of IL28B was only related to
the treatment outcome but was not related to the viral load.
A customized therapy for chronic hepatitis C based on genotype
and treatment viral response is the current treatment strategy
[1,2]. RVR is a useful predictor of SVR in treatment of chronic
hepatitis C with either conventional IFN or PegIFN plus RBV
therapies [5,10,11,38]. As for the predictor of RVR, previous
reports have shown baseline viral load was the single predictor
[38], or together with younger age, lower body weight and absence
of advanced fibrosis as predictors [5,13,39]. In the present study,
we found baseline viral load was the only clinical parameter as the
predictor for RVR. As for the SNPs of IL28B, it is again the
rs12979860, but not other SNPs, that was the predictor for RVR.
On the other hand, EVR was also an important negative response
guider for treatment[16]. In previous reports, only the baseline
viral load could predict the EVR [40]. In the present analysis, only
rs12979860 but not other SNPs nor other clinical parameters,
including baseline viral load, was the predictor for EVR. These
results again emphasized the significant impact of this SNP to the
treatment responses. Taken together, only the genotype of
rs12979860 is the predictor for RVR, EVR, ETR and SVR.
These results are consistent with the idea that SNPs of IL28B is
related to the immune responses after interferon-plus RBV
treatment [41].
Another interesting observation in our study was the different
impact of the CC genotype of rs12979860 on the SVR in patients
with or without RVR. In patients with RVR, only baseline viral
load but not the genotype of rs12979860 could predict the SVR.
This is an interesting observation. The possible explanation is the
CC genotype of rs12979860 led to the RVR with odds ratio of
10.52. As a result, the majority of patients with RVR were CC
genotypes. Therefore, the CC genotype lost their predictive ability
for SVR in this patient group with high prevalence of CC
genotype. On the contrary, in patients without RVR, only the
genotype of rs12979860 but not the baseline viral load could
predict the SVR. This group of patients without RVR was with
lower prevalence of CC genotype. Therefore, the CC genotype
could continue its influence and therefore predict the SVR in this
group of patients. This observation was quite similar to the recent
report about genotype 2/3 HCV infected patients who received
treatment that the genotype of rs12979860 is a single predictor for
SVR in patients without RVR [35].
Since the discovery of the strong association between SNPs of
IL28B and treatment outcome of chronic hepatitis C, a
Table 5. Factors predicted EVR to Peg-IFN/RBV treatment in
genotype I chronic hepatitis C patients by univariate and
multivariate Logistic regression analysis.
Baseline Predictors Odds Ratio 95% CI p value
Univariable HbA1c (%) 0.63 0.41–0.97 0.034
GGT (IU/L) 0.98 0.98–0.99 0.002
rs12979860 36.21 6.68–196.38 ,0.001
rs8099917 9.77 2.24–42.60 0.002
rs12980275 18.67 4.06–85.84 ,0.001
rs8105790 9.77 2.24–42.60 0.002
rs7248668 36.21 6.68–196.38 ,0.001
rs10853728 1.95 0.47–8.07 0.356
Multivariable rs12979860
CT/TT genotype 1
CC genotype 36.21 6.68–196.38 ,0.001
doi:10.1371/journal.pone.0018322.t005
Table 6. Factors predicted ETR to Peg-IFN/RBV treatment in
genotype I chronic hepatitis C patients by univariate and
multivariate Logistic regression analysis.
Baseline Predictors Odds Ratio 95% CI p value
Univariable Sex 2.53 0.90–7.13 0.079
BMI (Kg/m
2) 0.88 0.77–1.02 0.081
GGT (IU/L) 0.99 0.98–0.99 0.018
rs12979860 13.58 4.34–42.56 ,0.001
rs8099917 8.94 2.89–27.65 ,0.001
rs12980275 6.90 2.19–21.79 0.001
rs8105790 8.94 2.89–27.65 ,0.001
rs7248668 13.58 4.34–42.56 ,0.001
rs10853728 2.66 0.94–7.51 0.064
Multivariable Sex
female 1
male 3.12 0.98–9.95 0.055
rs12979860
CT/TT genotype 1
CC genotype 15.42 4.64–51.18 ,0.001
doi:10.1371/journal.pone.0018322.t006
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hepatitis C based on these SNPs had been proposed [22]. As
suggested by Dr. Afdhal et al, although IL28B genotyping is highly
predictive of SVR in HCV GT1 infected patients, its predictive
power at the individual patient level is far from absolute.
Therefore, IL28B genotyping should not be the sole factor in
deciding on a treatment strategy [45]. In addition, shortening of
treatment duration based on these SNPs together with other
clinical parameter is possible but there are insufficient data to
make recommendations [45]. However, the predictive ability of
IL28B genotypes is strong enough. Therefore, it is reasonable to
recommend a pre-treatment genotyping for SVR prediction.
Based on our results described previously, we suggested genotyp-
ing for rs12979860 rather than other SNPs of IL28B would be a
suitable genetic testing before starting treatment for patients with
GT1-HCV chronic infection.
On the other hand, though a strong association between IL28B
polymorphism and SVR had been repeated reported, the
underlying mechanisms are still unclear. Recent in-vitro report
had shown that IL28B could inhibit HCV replication in a dose-
and time- dependent manner and through the JAK-STAT
pathway [42]. Consequently, it had been found that IL28B
genotype is associated with differential expression of intrahepatic
interferon-stimulated genes in patients with chronic hepatitis C
[43]. Furthermore, serum IL-28A/B levels were significantly
higher in patients with chronic hepatitis C with good allele of
IL28B genotype [44]. All these evidences indicate both direct anti-
viral effect and immune-mediated effect of IL28B could be
affected by these polymorphisms. However, detailed mechanistic
understanding needs further investigation.
The limitation of this study was the retrospective nature of the
analysis. However, it is common to all the papers published on this
issue. The other limitation was that we had excluded the patients
who didn’t adhere to the 80/80/80 principle in order to investigate
the real effects of SNPs on the treatment response. However, this
exclusion would possibly ignore the possibilities that some patients
without 80/80/80 adherence were due to the effect of these SNPs
though till now there was no such report. Prospective controlled
studies would be necessary to evaluate the influence of different
SNPs of IL28B gene, especially rs12979869 and rs8077717, on
treatment outcome of patients with chronic hepatitis C.
In conclusion, our data demonstrated that the genotype of
rs12979860 is the most powerful predictor for RVR, EVR, ETR
and SVR among ten SNPs of IL28B in patients with GT1 HCV
infection treated with PegIFN/RBV. Furthermore, we also
demonstrated different impact of baseline viral load and genotype
of rs12979860 on SVR in patients with or without RVR. Based on
these results, we suggested that the genotyping of rs12979860 is
the suitable target for genetic testing before treatment for patients
with GT1-HCV chronic infection.
Table 7. Influences of SNPs of IL28B on the baseline viral load and liver fibrosis.
Genotypes of SNPs Baseline Viral load (IU/ml) Fibrosis stage (Metavir)
,0.4610
6 $0.4610
6 P value F0-F2 F3-F4 P value
rs12979860 CC 81 90 0.824 90 81 0.348
CT+TT 10 10 13 7
rs8099917 GG+GT 81 89 0.998 88 82 0.088
TT 10 11 15 6
rs12980275 AA 82 89 0.818 90 81 0.294
AG 9 11 13 7
rs8105790 TT 81 89 1.000 88 82 0.088
CC+CT 10 11 15 6
rs7248668 GG 80 91 0.637 91 80 0.565
AA+AG 11 9 12 8
rs10853728 CC 59 66 0.880 64 61 0.298
CG+GG 32 34 39 27
doi:10.1371/journal.pone.0018322.t007
Table 8. Influence of genotypes of rs12979860 on SVR in high and low baseline viral load.
Baseline Viral load rs12979860
Non-SVR
N( % )
SVR
N( % )
OR
(95% CI) Homogeneity of OR
a
Low viral load
(,0.4610
6 IU/ml)
CC 11 (13.6) 70 (86.4) 6.37 (1.6–25.6)
p=0.013
p=0.956
CT/TT 5 (50.0) 5 (50.0)
High viral load
($0.4610
6 IU/ml)
CC 36 (40.0) 54 (60.0) 5.99 (1.2–30.3)
p=0.020
CT/TT 8 (80.0) 2 (20.0)
aCochrans and Mantel-Haenszel statistics.
doi:10.1371/journal.pone.0018322.t008
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